Ciphergen Biosystems

University of Kentucky, biomarker research firm partner to fight ovarian cancer

Published in Medicine and Law Weekly, September 23rd, 2005

Ciphergen Biosystems, Inc., (CIPH) announced the signing of a research and collaboration agreement with the University of Kentucky.

The collaboration gives Ciphergen exclusive rights to license discoveries made during the agreement and is part of the University's ongoing research in ovarian cancer.

"This agreement allows us to expand our current research in oncology by working with Doctor van Nagell and his colleagues," said Gail Page, president and chief operating officer of Ciphergen. "The University of Kentucky is a major referral center for the treatment of gynecologic malignancies. We are very pleased to be collaborating in our mutual goal to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-09-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry